Holen Sie sich die Stockscreener-App
135.75
0.56%
0.76
Vorhandelsmarkt:
133.00
-2.75
-2.03%
Schlusskurs vom Vortag:
$134.99
Offen:
$123.9
24-Stunden-Volumen:
1.24M
Relative Volume:
2.32
Marktkapitalisierung:
$6.77B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-20.79
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+0.79%
1M Leistung:
+12.84%
6M Leistung:
+20.98%
1J Leistung:
+52.80%
1-Tages-Spanne:
$123.50
$137.85
1-Wochen-Bereich:
$123.50
$137.85
52-Wochen-Spanne:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
135.75 | 6.74B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome: Q3 Earnings Snapshot - New Haven Register
Will Axsome Therapeutics Inc. stock go up soonMarket Growth Summary & Safe Capital Investment Plans - newser.com
How Axsome Therapeutics Inc. (19X) stock moves in volatile trading sessionsQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Can machine learning forecast Axsome Therapeutics Inc. recoveryQuarterly Growth Report & Accurate Intraday Trading Signals - newser.com
How Axsome Therapeutics Inc. stock compares to industry benchmarksWeekly Investment Recap & Free Growth Oriented Trading Recommendations - newser.com
Decoding Axsome Therapeutics Inc (AXSM): A Strategic SWOT Insight - GuruFocus
Axsome Therapeutics Reports Strong Q3 2025 Growth - TipRanks
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion - Investing.com
Axsome Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Transcript : Axsome Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Axsome Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Axsome Therapeutics Q3 2025 reveals revenue beat, stock dips - Investing.com
Is Axsome Therapeutics Inc. forming a reversal pattern2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Axsome Therapeutics Saw Sales Jump But Losses Remain - Finimize
Market reaction to Axsome Therapeutics Inc.’s recent newsWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Axsome Therapeutics Q3 Net Loss Narrows, Revenue Rises - MarketScreener
Axsome Q3 2025 Financial Results: Revenue Beats, Loss WidensNews and Statistics - IndexBox
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025 - TipRanks
Earnings Flash (AXSM) Axsome Therapeutics Posts Q3 Net Loss $0.94 a Share, vs. FactSet Est of $0.82 Loss - MarketScreener
Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q3 Revenue $171.0M, vs. FactSet Est of $163.0M - MarketScreener
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Axsome Therapeutics Inc. stock momentum explainedJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Axsome Therapeutics Q3 net product revenue jumps 63% - MarketScreener
Axsome Therapeutics Inc. recovery potential after sell offJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
Will Axsome Therapeutics Inc. stock sustain high P E ratios2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Axsome Therapeutics Inc. stock volume spike explained2025 Dividend Review & Verified Entry Point Signals - newser.com
Historical volatility pattern of Axsome Therapeutics Inc. visualized2025 Key Lessons & Daily Technical Forecast Reports - newser.com
How Axsome Therapeutics Inc. (19X) stock reacts to Fed tighteningJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
How rising interest rates impact Axsome Therapeutics Inc. stock2025 Sector Review & Community Shared Stock Ideas - newser.com
Can Axsome Therapeutics Inc. stock continue upward trendJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
What Wall Street predicts for Axsome Therapeutics Inc. stock pricePortfolio Profit Report & Short-Term Trading Opportunity Alerts - newser.com
Is a relief rally coming for Axsome Therapeutics Inc. holders2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Is Axsome Therapeutics Inc. stock a buy on dips2025 Key Lessons & Weekly Watchlist for Hot Stocks - newser.com
Why hedge funds are buying Axsome Therapeutics Inc. stockWeekly Stock Report & Daily Volume Surge Trade Alerts - newser.com
State of New Jersey Common Pension Fund D Grows Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
How Axsome Therapeutics Inc. stock compares to market leadersQuarterly Profit Summary & Weekly High Conviction Ideas - newser.com
Is Axsome Therapeutics Inc. stock gaining market shareMarket Trend Summary & Consistent Income Trade Ideas - newser.com
Is Axsome Therapeutics Inc. stock attractive after correctionStock Surge & Risk Adjusted Buy/Sell Alerts - newser.com
How Axsome Therapeutics Inc. stock performs in rate cut cyclesMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Option Exercise |
8.02 |
19,220 |
154,144 |
26,449 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Option Exercise |
8.02 |
13,390 |
107,388 |
20,619 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Option Exercise |
8.02 |
12,774 |
102,447 |
20,003 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Sale |
120.17 |
19,220 |
2,309,667 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Sale |
118.77 |
13,390 |
1,590,330 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Sale |
118.84 |
12,774 |
1,518,062 |
7,229 |
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):